(S)-6-(2,3-Difluoro-5-(2-(1-methylazetidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine

ID: ALA4590333

PubChem CID: 137530126

Max Phase: Preclinical

Molecular Formula: C20H25F2N3

Molecular Weight: 345.44

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1cc(N)nc(CCc2cc(CC[C@H]3CCN3C)cc(F)c2F)c1

Standard InChI:  InChI=1S/C20H25F2N3/c1-13-9-16(24-19(23)10-13)5-4-15-11-14(12-18(21)20(15)22)3-6-17-7-8-25(17)2/h9-12,17H,3-8H2,1-2H3,(H2,23,24)/t17-/m0/s1

Standard InChI Key:  STGWAFUVRUKRNW-KRWDZBQOSA-N

Molfile:  

 
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   14.2321   -2.4000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2309   -3.2274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9458   -3.6402    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.6623   -3.2269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6594   -2.3963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9440   -1.9872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5161   -3.6393    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.9416   -1.1622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.3774   -3.6383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0912   -3.2247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8063   -3.6361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8030   -4.4595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5173   -4.8708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2320   -4.4572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2281   -3.6278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5132   -3.2202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5182   -5.6958    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   19.9405   -3.2116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0879   -4.8710    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   20.6570   -3.6205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3694   -3.2044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1665   -3.4164    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.3759   -2.6184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5780   -2.4089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.5815   -4.1295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  2  7  1  0
  6  8  1  0
  4  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 11  1  0
 13 17  1  0
 15 18  1  0
 12 19  1  0
 18 20  1  0
 21 20  1  1
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 21  1  0
 22 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4590333

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 345.44

Molecular Weight (Monoisotopic): 345.2017

AlogP: 3.67

#Rotatable Bonds: 6

Polar Surface Area: 42.15

Molecular Species: BASE

HBA: 3

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.77

CX LogP: 4.35

CX LogD: 2.29

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.87

Np Likeness Score: -0.40

References

1. Do HT, Li H, Chreifi G, Poulos TL, Silverman RB..  (2019)  Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.,  62  (5): [PMID:30802056] [10.1021/acs.jmedchem.8b02032]

Source

Source(1):

• Scientific Literature